Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis

Juichiro Nakayama, Tetsuya Koga, Masutaka Furue

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs. Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy. Both systolic and diastolic blood pressures of these 13 patients were decreased significantly after 4 weeks of nifedipine therapy, and blood pressure was maintained within the normal range thereafter for 25 months. The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.

Original languageEnglish
Pages (from-to)563-568
Number of pages6
JournalEuropean Journal of Dermatology
Volume8
Issue number8
Publication statusPublished - Dec 1 1998

Fingerprint

Nifedipine
Psoriasis
Cyclosporine
Tablets
Hypertension
Gingival Hyperplasia
Blood Pressure
Therapeutics
Blood Urea Nitrogen
Calcium Channel Blockers
Antihypertensive Agents
Reference Values
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis. / Nakayama, Juichiro; Koga, Tetsuya; Furue, Masutaka.

In: European Journal of Dermatology, Vol. 8, No. 8, 01.12.1998, p. 563-568.

Research output: Contribution to journalArticle

@article{6cda4fd9327241eeb3ad853f9fd9f26f,
title = "Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis",
abstract = "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs. Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy. Both systolic and diastolic blood pressures of these 13 patients were decreased significantly after 4 weeks of nifedipine therapy, and blood pressure was maintained within the normal range thereafter for 25 months. The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.",
author = "Juichiro Nakayama and Tetsuya Koga and Masutaka Furue",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "8",
pages = "563--568",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "John Libbey Eurotext",
number = "8",

}

TY - JOUR

T1 - Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis

AU - Nakayama, Juichiro

AU - Koga, Tetsuya

AU - Furue, Masutaka

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs. Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy. Both systolic and diastolic blood pressures of these 13 patients were decreased significantly after 4 weeks of nifedipine therapy, and blood pressure was maintained within the normal range thereafter for 25 months. The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.

AB - Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs. Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy. Both systolic and diastolic blood pressures of these 13 patients were decreased significantly after 4 weeks of nifedipine therapy, and blood pressure was maintained within the normal range thereafter for 25 months. The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.

UR - http://www.scopus.com/inward/record.url?scp=0032443911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032443911&partnerID=8YFLogxK

M3 - Article

C2 - 9889429

AN - SCOPUS:0032443911

VL - 8

SP - 563

EP - 568

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 8

ER -